The similar variation of DNT cells and CD4, as well as other immune actors, may improve the reliability of lymphocyte assessment and warrants further investigation of DNTs as a potential target in checkpoint inhibitor resistant melanoma. The gene discussed is CD4; the disease is melanoma.